1,689 reports of this reaction
7.0% of all ROMIPLOSTIM reports
#2 most reported adverse reaction
PLATELET COUNT DECREASED is the #2 most commonly reported adverse reaction for ROMIPLOSTIM, manufactured by Amgen, Inc. There are 1,689 FDA adverse event reports linking ROMIPLOSTIM to PLATELET COUNT DECREASED. This represents approximately 7.0% of all 24,148 adverse event reports for this drug.
Patients taking ROMIPLOSTIM who experience platelet count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLATELET COUNT DECREASED is moderately reported among ROMIPLOSTIM users, representing a notable but not dominant share of adverse events.
In addition to platelet count decreased, the following adverse reactions have been reported for ROMIPLOSTIM:
The following drugs have also been linked to platelet count decreased in FDA adverse event reports:
PLATELET COUNT DECREASED has been reported as an adverse event in 1,689 FDA reports for ROMIPLOSTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLATELET COUNT DECREASED accounts for approximately 7.0% of all adverse event reports for ROMIPLOSTIM, making it one of the most commonly reported side effect.
If you experience platelet count decreased while taking ROMIPLOSTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.